MeiraGTx to receive up to $375 million in non-dilutive cash and up to $25 million in equity investment Following regulatory approval, Oberland Capital to receive low single-digit capped royalties...
LONDON and NEW YORK, May 14, 2026 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical-stage genetic medicines company, today announced that the Compensation Committee...
Received FDA Breakthrough Therapy Designation for AAV2-hAQP1 Reported positive three-year data from the Phase 1 AQUAx study of AAV2-hAQP1 for the treatment of grade 2/3 late radiation-induced xerostomia...
Barchart Research What to Expect from MGTX Earnings MGTX Generated May 11, 2026 Current Price $9.90 EPS Estimate $$-0.43 Consensus Rating Strong Buy Average Move 7.24% MeiraGTx: Wall Street Celebrates...
LONDON and NEW YORK, April 16, 2026 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical-stage genetic medicines company, today announced the pricing of an underwritten...
Company entered into an asset purchase agreement with Johnson & Johnson (J&J) to acquire all interests in botaretigene sparoparvovec (bota-vec) for the treatment of X-linked retinitis pigmentosa (XLRP)...
Clinically meaningful improvements in xerostomia symptoms measured by PRO Xerostomia Questionnaire (XQ) maintained out to 3 years post treatment with AAV-hAQP1 for both bilateral and unilateral cohorts...
- Presentation to include 3-year data from all cohorts of the Phase 1 AQUAx Clinical Study - Cohort-level data and individual patient data from bilateral and unilateral cohorts will be presented for...
FDA granted Breakthrough Therapy Designation for AAV2-hAQP1 for the treatment of Grade 2 and Grade 3 late xerostomia caused by radiotherapy for cancers of the upper aerodigestive tract MeiraGTx to...
Barchart Research What to Expect from MGTX Earnings MGTX Generated March 25, 2026 Current Price $7.62 EPS Estimate $-0.60 Consensus Rating Strong Buy Average Move 7.98% MeiraGTx Faces Mounting Losses as...